PT-141
10 mg
Research Use Only
For research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. Must be 21 or older to purchase.
Measurement Key
mg = milligram; mcg = microgram; 1 mg = 1,000 mcg. mL = liquid volume. A U-100 syringe has 100 marked volume units per mL: one marking is 0.01 mL and ten are 0.10 mL. These markings are NOT peptide International Units (IU). A physical syringe may not have one-unit or half-unit graduations; do not imply it can measure a value more precisely than its scale permits. Concentration = total amount / measured FINAL volume. Quantity in a sample = concentration × sample volume. Required volume = a protocol-specified quantity / verified concentration. The calculator checks arithmetic only; it cannot select a clinical dose or establish suitability, stability or sterility.
Research Information
Contents
10 mg PT-141 / bremelanotide; powder vial.
Clinical evidence and research limitations
RECONNECT trials found improved sexual desire and reduced related distress in premenopausal women with hypoactive sexual desire disorder. These findings concern the studied bremelanotide formulation, not proof that this research vial treats sexual dysfunction in every population.
Dosing evidence
Approved Vyleesi reference only: 1.75 mg as needed at least 45 minutes before anticipated sexual activity; no more than once per 24 hours; more than eight doses/month is not recommended. This is not a preparation or administration instruction for the research vial.
Reconstitution
This is a powder-vial calculation reference, not a validated preparation recipe. Confirm the exact formulation, compatible diluent, final volume, container capacity, mixing method and storage with the manufacturer. Do not interpret the example as a direction to add that volume of BAC water.
Measurement example
MATHEMATICAL EXAMPLE ONLY: assuming 10 mg in a measured FINAL volume of 3 mL, concentration = 3.33333 mg/mL. One U-100 marking (0.01 mL) represents 33.3333 mcg. Ten U-100 markings (0.10 mL) represent 0.333333 mg. These amounts describe the solution; they are not recommended doses. Use unrounded inputs for further calculations.
Possible side effects
Vyleesi labeling includes nausea, flushing, headache, transient blood-pressure increases and skin pigmentation changes. Uncontrolled hypertension or known cardiovascular disease are contraindications.
Storage
Follow the original lot-specific supplier instructions before and after preparation. Temperature, light protection, freezing limits and discard date: insufficient data to verify. The calculation volume does not establish stability or a use-by period.
Sources
Source access date: October 25, 2026. Secondary calculation references (peptidedosages.com) are community resources, not clinical trials. Their example volumes do not validate these products.
Responding to possible adverse effects: The side-effect summaries are incomplete and do not establish the safety of the inventory. Unknown risks must not be described as "no side effects." For anyone experiencing breathing difficulty, facial/throat swelling, fainting, severe persistent abdominal pain or other severe symptoms after an exposure, seek urgent medical care and provide the product/lot details.
Preparation and Handling Information
The original product instructions must establish substance identity, component ratio, excipients, compatible diluent, required amount, final volume, mixing method, container suitability, storage and discard interval. A 3 mL container does not automatically require 3 mL water. Any powder displacement and final-volume instructions must be accounted for. Do not transfer the storage rules for a branded finished medicine to a different research powder. No universal refrigerated shelf life, freezer shelf life or "28 days after mixing" period is established for this catalog. Lack of visible particles is not proof of sterility. Do not use a damaged, leaking, unexpectedly altered or undocumented preparation.